BabyBio columns for ion exchange chromatography (IEX) simplify purification processes.

WorkBeads SEC resins are agarose-based beads optimized for preparative-scale separations.

Monoclonal antibody (mAb) therapies dominate the fastest-growing biopharmaceutical market.

The page describes methods to optimize protein separations using hydrophobic interaction chromatography.

Monoclonal antibodies (mAbs) are driving rapid changes in medical therapies.

The page explains how protein A resins improve antibody-drug conjugate purification.

Anion exchange chromatography separates full and empty capsids, as described here.

Bio-Works Technologies AB and BIA d.o.o. have signed a distribution agreement.

The demand for sustainable pharmaceutical production is growing.

Peter previously led Pharmacia Biotech, Amersham, and GE Healthcare’s Life Sciences division before becoming an entrepreneur and board member.

Bio-Works develops WorkBeads chromatography resins and GoBio pre-packed columns for purifying monoclonal antibodies, proteins, peptides, oligos, viruses, and vaccines. Their resins feature tight bead and pore size distribution for high purity, binding capacity, and flow rates, used in research and industrial production.

This page provides contact details for local Bio-Works distributors.

Bio-Works manufactures chromatography resins for biopharmaceutical purification and supports customers with high-quality products.

Bio-Works Technologies AB is a publicly traded company.

Whistleblowing refers to reporting/“blowing the whistle” if there is, will be or has been any form of serious misconduct within the Bio-Works operations such as may cause great harm to Bio-Works and/or its stakeholders.

Bio-Works shows revenue growth and improved operating results for the first nine months of 2026 compared to the same period last year. The third quarter alone saw weaker deliveries and earnings, though the company reports strong order intake. Performance trends indicate progress in key financial metrics despite seasonal fluctuations.

Oct 2026News Powered by CisionNews article

Bio-Works Technologies AB partners with a major US biotechnology company to develop a new medicine. The collaboration includes a total order valued at **SEK 2.8 million**. The Swedish firm specializes in advanced bioprocessing solutions for pharmaceutical innovation.

Aug 2026News Powered by CisionNews article

Bio-Works Technologies AB reports a 53% increase in net sales to **20.0 MSEK** in Q2 2026, up from **13.1 MSEK** in the same period last year. The company’s operating profit improved to **-3.1 MSEK**, narrowing losses from **-7.6 MSEK** in Q2 2025. The results reflect continued growth amid ongoing operational adjustments.

Aug 2026News Powered by CisionNews article

Bio-Works Technologies AB names Eva Lindskog as its new Chief Executive Officer. The appointment follows a Board of Directors decision and takes effect on 1 November 2026. Lindskog assumes leadership of the biotechnology company, succeeding the outgoing CEO.

Aug 2026News Powered by CisionNews article